Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2020

Nov 09, 2020

SELL
$264.77 - $305.71 $8.19 Million - $9.45 Million
-30,925 Closed
0 $0
Q2 2020

Aug 10, 2020

SELL
$258.66 - $342.55 $12.3 Million - $16.3 Million
-47,639 Reduced 60.64%
30,925 $8.27 Million
Q1 2020

May 14, 2020

SELL
$268.85 - $341.04 $9.15 Million - $11.6 Million
-34,019 Reduced 30.22%
78,564 $24.9 Million
Q4 2019

Feb 12, 2020

SELL
$220.06 - $304.07 $9.52 Million - $13.2 Million
-43,249 Reduced 27.75%
112,583 $33.4 Million
Q3 2019

Nov 08, 2019

BUY
$217.44 - $243.88 $2.18 Million - $2.45 Million
10,041 Added 6.89%
155,832 $36.3 Million
Q2 2019

Jul 25, 2019

SELL
$219.29 - $241.72 $2.38 Million - $2.63 Million
-10,876 Reduced 6.94%
145,791 $34.1 Million
Q1 2019

May 08, 2019

SELL
$216.71 - $338.96 $400,480 - $626,398
-1,848 Reduced 1.17%
156,667 $37 Million
Q4 2018

Feb 05, 2019

SELL
$278.5 - $352.75 $235,889 - $298,779
-847 Reduced 0.53%
158,515 $47.7 Million
Q3 2018

Nov 13, 2018

BUY
$293.51 - $383.83 $1.02 Million - $1.33 Million
3,478 Added 2.23%
159,362 $56.3 Million
Q2 2018

Aug 07, 2018

BUY
$257.52 - $306.91 $93,479 - $111,408
363 Added 0.23%
155,884 $45.2 Million
Q1 2018

May 08, 2018

BUY
$260.13 - $367.91 $9.11 Million - $12.9 Million
35,039 Added 29.08%
155,521 $42.6 Million
Q4 2017

Feb 12, 2018

SELL
$307.64 - $344.58 $7.09 Million - $7.94 Million
-23,057 Reduced 16.06%
120,482 $38.4 Million
Q3 2017

Nov 08, 2017

BUY
$281.15 - $329.69 $40.4 Million - $47.3 Million
143,539
143,539 $44.9 Million

Others Institutions Holding BIIB

About BIOGEN INC.


  • Ticker BIIB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 144,000,992
  • Market Cap $25B
  • Description
  • Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...
More about BIIB
Track This Portfolio

Track Rothschild & CO Asset Management Us Inc. Portfolio

Follow Rothschild & CO Asset Management Us Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rothschild & CO Asset Management Us Inc., based on Form 13F filings with the SEC.

News

Stay updated on Rothschild & CO Asset Management Us Inc. with notifications on news.